TORONTO, Sept. 19, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company“), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA)…


Previous articleFrom Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan
Next articlePT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The Stress Response System